Abbott (ABT) Stock Rated Buy on Strong Diabetes Trial Results

Abbott Laboratories (NYSE:ABT) ranks among the best most active stocks to buy right now. Following encouraging results from Abbott Laboratories (NYSE:ABT)’s FreeDM trial, Benchmark reiterated a Buy rating and $145 price target for the company’s shares on March 13. In comparison to individuals using whole blood glucose meters with fingerstick blood samples, the trial demonstrated that patients with Type 2 diabetes on basal insulin therapy who employed FreeStyle Libre continuous glucose monitoring technology ...